Table 1.
The clinical features of patients in model cohort and validation cohort.
| TCGA cohort | GSE62254 cohort | P value | |
|---|---|---|---|
| Patient number | 265 | 279 | |
| Death [n(%)] | 98(37.0) | 152(54.5) | <0.001 |
| Survival time for living patients(mean ± SD, month) | 19.6(12.3,32.2) | 60.0(49.0,76.0) | <0.001 |
| Survival time for dead patients (mean ± SD, month) | 10.6(6.0,15.4) | 9.4(3.9,18.1) | 0.827 |
| Age (mean ± SD, year) | 64.4 ± 10.6 | 61.9 ± 11.3 | 0.008 |
| Male [(n)%] | 175(66.0) | 181(94.9) | 0.776 |
| AJCC Stage (IV) | 23 | 75 | <0.001 |
| AJCC Stage (III) | 103 | 86 | |
| AJCC Stage (II) | 91 | 89 | |
| AJCC Stage (I) | 41 | 29 | |
| AJCC Stage (NA) | 7 | 0 | |
| AJCC PT (T4) | 66 | 20 | <0.001 |
| AJCC PT (T3) | 121 | 84 | |
| AJCC PT (T2) | 62 | 175 | |
| AJCC PT (T1) | 16 | 0 | |
| AJCC PT (NA) | 0 | 0 | |
| AJCC PN (N3) | 53 | 50 | 0.006 |
| AJCC PN (N2) | 55 | 73 | |
| AJCC PN (N1) | 67 | 119 | |
| AJCC PN (N0) | 88 | 37 | |
| AJCC PN (NA) | 2 | 0 | |
| AJCC PM (M1) | 22 | 27 | 0.578 |
| AJCC PM (M0) | 243 | 252 | |
| AJCC PM (NA) | 0 | 0 | |
| Targeted molecular therapy (Yes) | 78 | NA | |
| Targeted molecular therapy (No) | 79 | NA | |
| Targeted molecular therapy (NA) | 108 | NA | |
| Radiation treatment adjuvant (Yes) | 0 | NA | |
| Radiation treatment adjuvant (No) | 155 | NA | |
| Radiation treatment adjuvant (NA) | 110 | NA | |
| Barretts esophagus (Yes) | 12 | NA | |
| Barretts esophagus (No) | 151 | NA | |
| Barretts esophagus (NA) | 102 | NA | |
| H pylori infection (Yes/No/NA) | 15 | NA | |
| H pylori infection (No) | 117 | NA | |
| H pylori infection (NA) | 133 | NA |
Note: NA, missing data; SD: standard deviation; AJCC: American Joint Committee on Cancer.